Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
IMVT Stock Chart & Stats
$27.75
-$0.80(-3.25%)
At close: 4:00 PM EST
$27.75
-$0.80(-3.25%)
Day’s Range― - ―
52-Week Range$12.72 - $29.25
Previous CloseN/A
Volume171.97K
Average Volume (3M)1.25M
Market Cap
$5.65B
Enterprise Value$4.44B
Total Cash (Recent Filing)$994.52M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Jun 03, 2026EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding203,532,180
10 Day Avg. Volume934,095
30 Day Avg. Volume1,246,280
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)3.66
Price to Sales (P/S)0.00
P/FCF Ratio-6.88
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-43.99K
Enterprise Value/Ebitda-9.23
Forecast
1Y Price Target
$38.89Price Target Upside40.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.67
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial CatalystA topline Phase 2b readout in difficult-to-treat rheumatoid arthritis is a key catalyst, with faster-than-expected enrollment signaling strong unmet need and increasing the chance of a meaningful positive efficacy outcome.
Financial RunwayA substantial capital raise provides financial stability and a runway to advance late-stage programs and support a potential commercial launch in Graves' disease.
Mechanism DifferentiationIMVT-1402's design to achieve deeper, dose-dependent IgG suppression than current competitors may translate into stronger clinical benefit across multiple autoimmune indications, supporting a differentiated profile.
Bears Say
Commercial Risk In Thyroid Eye DiseaseThyroid eye disease faces a high efficacy bar driven by existing therapies, and discontinuation of a competitor's program for futility raises uncertainty about commercial viability in that indication.
Financial Risk And Market PressureHigh cash burn combined with meaningful short interest increases the company's financial risk profile and could place downward pressure on the stock if development or regulatory timelines slip.
Trial Design And Regulatory RiskThe Phase 3 program's dosing schedule and lack of a pre-specified futility analysis introduce execution and regulatory risks, since the primary efficacy assessment follows a protocol-specified dose reduction in the second half of the trial.
Immunovant News
IMVT FAQ
What was Immunovant’s price range in the past 12 months?
Immunovant lowest stock price was $12.72 and its highest was $29.25 in the past 12 months.
What is Immunovant’s market cap?
Immunovant’s market cap is $5.65B.
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is Jun 03, 2026 which is in 91 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on Feb 06, 2026. The company reported -$0.61 earnings per share for the quarter, beating the consensus estimate of -$0.713 by $0.103.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -0.61.
How many shares outstanding does Immunovant have?
Immunovant has 203,532,180 shares outstanding.
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -$0.61 in its last earnings report, beating expectations of -$0.713. Following the earnings report the stock price went up 12.427%.
Which hedge fund is a major shareholder of Immunovant?
Currently, no hedge funds are holding shares in IMVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunovant Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.89 (40.14% Upside)
$38.89 (40.14% Upside)
Blogger Sentiment
Bullish
IMVT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 934.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $349.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.3%
Last 30 Days ▲ 11.1%
Last 30 Days ▲ 11.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.70%
12-Months-Change
Fundamentals
Return on Equity
-69.35%
Trailing 12-Months
Asset Growth
150.01%
Trailing 12-Months
Company Description
Immunovant
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
IMVT Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial positive momentum driven by exceptionally strong Phase II brepocitinib data in cutaneous sarcoidosis, multiple fully enrolled studies and a solid cash position to fund upcoming registrational activity. Key operational highlights include the brepo NDA in dermatomyositis, fully enrolled 1402 D2T RA and mosliciguat PH‑ILD studies, and constructive legal progress ahead of a March jury trial. Offsetting risks are the small size and baseline imbalances of the CS Phase II study (creating uncertainty aboutPhase III translation), ongoing litigation and evidentiary motions, continued high operating spend and typical regulatory/development timing uncertainties. Overall, the positives (clinical wins, pipeline momentum, enrollment success and cash runway) materially outweigh the programmatic and legal uncertainties identified on the call.View all IMVT earnings summariesIMVT Stock 12 Month Forecast
Average Price Target
$38.89
▲(40.14% Upside)
Technical Analysis
Protagonist Therapeutics
―
Crinetics Pharmaceuticals
―
Mirum Pharmaceuticals
―
Kymera Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
Currently, No data available
---